Hebei Lansheng Biotech Co., Ltd.
Beijing Multigrass Formulation Co., Ltd.

Bayer responds to EFSA’s conclusion on neonicotinoids risks to beesqrcode

Mar. 2, 2018

Favorites Print
Forward
Mar. 2, 2018
Bayer said it “fundamentally disagrees” with EFSA’s updated risk assessment conclusions for the active substances imidacloprid and clothianidin. EFSA’s findings place it outside the current mainstream science on bee health, as represented by recent similar assessments done by agencies such as the U.S. EPA and Canadian PMRA. These assessments have shown conclusively that neonicotinoid products can be used by farmers to protect their valuable crops without harming honey bee colonies. 
 
Unfortunately, EFSA chose to base its assessment on an unworkable guidance document that makes it impossible to field a study that would not find risk, despite repeated requests by Member States for a review of this guidance. EFSA’s conclusions can therefore not be used as a measuring stick to justify further neonicotinoid restrictions. While challenges to bee health remain due to a number of factors, the fact remains that the total number of beehives in the EU is continuing to rise. Bayer will continue to work with farmers, beekeepers and regulators on solutions that will have a positive impact on bee health.
 

Picture 0/1200

More from AgroNews

Magazine

2020 India Pesticide Suppliers Guide 2020 Market Insight
2020 CRO & CRAO Manual 2020 Biologicals Special
2020 Latin America Focus 2020 Formulation & Adjuvant Technology
Subscribe Comment

Subscribe 

Subscribe Email: *
Name:
Mobile Number:  

Comment  

Picture 0/1200

Subscribe to daily email alerts of AgroNews.